Fundraising FoxXenimmune
Cambridge, US · 1 known investors
Find your way into Xenimmune
Sign up to see every warm intro you have to Xenimmune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xenimmune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
Founders & leadership
RJ
Richard J. LimChief Executive OfficerRichard J. Lim is CEO of XenImmune, an immuno-oncology company. With over 30 years in life sciences, he co-founded Cure Ventures, a venture capital firm focused on drug discovery and development companies, alongside Lou Tartaglia and Dave Fallace.
Investors · 1
Frequently asked questions
- What does Xenimmune do?
- XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.
- Who are Xenimmune's investors?
- Xenimmune's investors include Cure Ventures.
- Where is Xenimmune headquartered?
- Xenimmune is headquartered in Cambridge, US.